Capturing Value from Health Technologies in Lean Times

The adoption of new health technologies brings potential improvements to quality of life as well as new costs for provincial healthcare systems. An appropriate evidence-based framework for adoption decisions therefore can go a long way to improving value for money in our health systems. While making decisions to adopt new technologies is a highly politicized process, these decisions must nonetheless strive to make use of all available evidence, including economic evaluations that consider all the costs and consequences of new technologies for society as a whole, including medical, ethical, legal, social and cultural. This Commentary focuses on an emerging, evidence-based policy tool called Health Technology Assessment (HTA). HTA helps inform decisionmaking on how to balance demand and supply pressures for new technologies within a health-system budget. The overarching objective is to obtain the greatest health gains within fiscal constraints by grounding decisions in a clear, transparent and coordinated process. In Canada, the number of entities engaged in various forms of HTA has been growing, and more and more people in healthcare are becoming exposed to the techniques involved. This progress and capacity growth is encouraging. However, rather than counting on a natural slowing of healthcare costs to relieve fiscal pressures, the provinces would be better off grounding their efforts in clear and coordinated HTA processes that incorporate economic evaluation and meaningful collaborative deliberation based on available evidence. This Commentary also looks at examples of HTA experience outside Canada and highlights lessons for Ottawa and the provinces. At present, the National Institute for Health and Care Excellence in the UK is by far the most advanced example of an attempt to utilize a consistent framework for technology adoption in a government-funded healthcare system. The UK’s current transition toward “value-based pricing” is another positive example of how HTA economic evaluation can be used to inform technology adoption in a more constructive way than with traditional “yes” or “no” recommendations. Canadian HTA agencies should draw as much as possible on existing international evidence – from randomized clinical trials, post-market assessments, clinical guidelines, etc. – and maintain close relationships with their counterparts in other countries and international organizations. Finally, HTA frameworks in Canada also must aim to encourage greater stakeholder participation and relationship development.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.